MCID: ADL096
MIFTS: 40

Adult Hepatocellular Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Adult Hepatocellular Carcinoma

MalaCards integrated aliases for Adult Hepatocellular Carcinoma:

Name: Adult Hepatocellular Carcinoma 12 15
Adult Primary Hepatocellular Carcinoma 12 71
Adult Hepatoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0070328
NCIt 49 C7956
UMLS 71 C0279607

Summaries for Adult Hepatocellular Carcinoma

Disease Ontology : 12 A hepatocellular carcinoma that is characterized by hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure and often develops in the setting of chronic necro-inflammation.

MalaCards based summary : Adult Hepatocellular Carcinoma, also known as adult primary hepatocellular carcinoma, is related to hepatocellular carcinoma and pediatric hepatocellular carcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Adult Hepatocellular Carcinoma is OR10S1 (Olfactory Receptor Family 10 Subfamily S Member 1). The drugs Sunitinib and Megestrol acetate have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and endothelial, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Adult Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Adult Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 11.8
2 pediatric hepatocellular carcinoma 11.4
3 gestational trophoblastic neoplasm 9.8 LGALS1 AFP
4 graves disease 1 9.8
5 non-alcoholic fatty liver disease 9.8
6 sarcoma 9.8
7 liver disease 9.8
8 fibrolamellar carcinoma 9.8
9 fatty liver disease 9.8
10 ectopic pregnancy 9.7 LGALS1 AFP
11 placenta disease 9.6 LGALS1 AFP

Graphical network of the top 20 diseases related to Adult Hepatocellular Carcinoma:



Diseases related to Adult Hepatocellular Carcinoma

Symptoms & Phenotypes for Adult Hepatocellular Carcinoma

UMLS symptoms related to Adult Hepatocellular Carcinoma:


fever, abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.4 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.4 AFP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.4 OR10S1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.4 OR10S1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.4 OR10S1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.4 AFP
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.4 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.4 AFP
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.4 AFP OR10S1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.4 OR10S1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.4 OR10S1

Drugs & Therapeutics for Adult Hepatocellular Carcinoma

Drugs for Adult Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2, Phase 3 557795-19-4, 341031-54-7 5329102
2
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
3
Iodine Approved, Investigational Phase 3 7553-56-2 807
4 Ethiodized oil Approved, Investigational Phase 3 8008-53-5
5
Sodium citrate Approved, Investigational Phase 3 68-04-2
6
Tamoxifen Approved Phase 3 10540-29-1 2733526
7
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
8
leucovorin Approved Phase 3 58-05-9 6006 143
9
Pravastatin Approved Phase 3 81093-37-0 54687
10
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
11
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
12
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
14 Nolatrexed Investigational Phase 3 147149-76-6
15 Central Nervous System Stimulants Phase 3
16 Contraceptives, Oral Phase 3
17 Contraceptive Agents Phase 3
18
Megestrol Phase 3 3562-63-8 19090 3080587
19 cadexomer iodine Phase 3
20 Citrate Phase 3
21 Estrogen Antagonists Phase 3
22 Estrogen Receptor Antagonists Phase 3
23 Estrogen Receptor Modulators Phase 3
24 Estrogens Phase 3
25 Vitamin B Complex Phase 3
26 Folate Phase 3
27 Folic Acid Antagonists Phase 3
28 Vitamin B9 Phase 3
29 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
30 Lipid Regulating Agents Phase 3
31 Hypolipidemic Agents Phase 3
32 Anticholesteremic Agents Phase 3
33 Anti-Bacterial Agents Phase 3
34
Liposomal doxorubicin Phase 3 31703
35 Antibiotics, Antitubercular Phase 3
36 Protein Kinase Inhibitors Phase 3
37 Liver Extracts Phase 3
38
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
39
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
40
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
41
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
42
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
43
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
44
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
45
Lenograstim Approved, Investigational Phase 2 135968-09-1
46
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
47
Epirubicin Approved Phase 2 56420-45-2 41867
48
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
49
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
50
Ethanol Approved Phase 2 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 Randomised Trial of Adjuvant Hepatic Intra-Arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma Unknown status NCT00027768 Phase 3
2 A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma Unknown status NCT00079027 Phase 3 doxorubicin hydrochloride
3 TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer Unknown status NCT01324076 Phase 3 doxorubicin-eluting beads;sorafenib tosylate
4 Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma Completed NCT00041275 Phase 3 megestrol acetate
5 Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma Completed NCT00003424 Phase 3 tamoxifen citrate
6 Adjuvant Treatment by Intra-arterial Injection of Lipiodol-labeled Iodine-131 in Preventing Recurrence of Hepatocellular Carcinoma After Curative Treatment Completed NCT00870558 Phase 3 ethiodized oil
7 A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin Completed NCT00012324 Phase 3 doxorubicin hydrochloride;nolatrexed dihydrochloride
8 Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma Completed NCT01075555 Phase 3 pravastatin sodium;sorafenib tosylate
9 A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE) Completed NCT01164202 Phase 2, Phase 3 sunitinib malate;Placebo
10 A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study) Completed NCT01829035 Phase 3
11 A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC) Completed NCT00109954 Phase 3 cisplatin
12 Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma Recruiting NCT01730937 Phase 3 sorafenib tosylate
13 Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting NCT01015833 Phase 3 Doxorubicin Hydrochloride;Sorafenib Tosylate
14 Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial Terminated NCT01405573 Phase 3 sorafenib
15 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
16 Proof-of-Concept Phase II Study to Evaluate the Anti-Tumor Activity of Sorafenib Along With Pathological and Molecular Changes in Tumor Samples From Patients With Resectable Hepatocellular Carcinoma Unknown status NCT01182272 Phase 2 sorafenib tosylate
17 Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients Unknown status NCT00132041 Phase 2
18 Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02418988 Phase 2 TACE plus rAd-p53 artery injection;TACE
19 Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer) Unknown status NCT00553683 Phase 1, Phase 2 cyclophosphamide;poly ICLC
20 A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma Unknown status NCT00471484 Phase 2 doxorubicin hydrochloride;fluorouracil;oxaliplatin
21 Hepatocellular Carcinoma Family of Tumours In Children / Adolescents and Young Adults Unknown status NCT00276705 Phase 2 cisplatin;cyclophosphamide;doxorubicin hydrochloride;thalidomide
22 A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed NCT02024087 Phase 1, Phase 2 Dalantercept plus sorafenib
23 Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma Completed NCT00005629 Phase 1, Phase 2
24 A Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation Completed NCT00321594 Phase 1, Phase 2 belinostat
25 A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers Completed NCT00101036 Phase 2 lapatinib ditosylate
26 A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma Completed NCT00087282 Phase 2 alvocidib;irinotecan hydrochloride
27 Phase II Trial of PS-341 in Patients With Hepatocellular Carcinoma Completed NCT00077441 Phase 2 bortezomib
28 Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Completed NCT00006010 Phase 2 docetaxel;gemcitabine hydrochloride
29 Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression Completed NCT00006006 Phase 2 thalidomide
30 A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hepatocellular Carcinoma Completed NCT00004108 Phase 2 exatecan mesylate
31 A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer Completed NCT00128596 Phase 2 arsenic trioxide
32 Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control Completed NCT00040898 Phase 2
33 A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer Completed NCT00003557 Phase 2 dolastatin 10
34 A Phase II Study of ZD1839 (Iressa, Gefitinib, NSC 715055) in Advanced Unresectable Hepatocellular Carcinoma Completed NCT00071994 Phase 2 gefitinib
35 A Phase II Study Of Epirubicin And Thalidomide In Unresectable Or Metastatic Hepatocellular Carcinoma Completed NCT00058487 Phase 2 epirubicin hydrochloride;thalidomide
36 A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma Completed NCT00054262 Phase 2 T900607
37 A Phase II Study of Oxaliplatin in Hepatocellular Cancer Completed NCT00052364 Phase 2 oxaliplatin
38 A Phase II Study of Octreotide Acetate for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma Completed NCT00257426 Phase 2 octreotide acetate
39 A Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma Completed NCT00238394 Phase 2 cediranib maleate
40 Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients Completed NCT00875615 Phase 2 Carboplatin;Cisplatin;Sorafenib
41 Continuous Sunitinib Treatment in Patients With Unresectable Hepatocellular Carcinoma A Multicenter Phase II Trial Completed NCT00514228 Phase 2 sunitinib malate
42 Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma Completed NCT00335829 Phase 2 chemotherapy;embolization therapy
43 An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial) Completed NCT00956930 Phase 2 Doxorubicin
44 A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas Completed NCT00107536 Phase 2 lapatinib ditosylate
45 A Phase II Study Of SB-715992 (NSC 727990) In Patients With Locally Advanced, Recurrent Or Metastatic Hepatocellular Carcinoma Completed NCT00095992 Phase 2 ispinesib
46 A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma Completed NCT00022334 Phase 1, Phase 2
47 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
48 Bevacizumab (RhuMAB-VEGF) In Hepatocellular Cancer For Patients With Unresectable Tumor (Without Invasion Of The Main Portal Vein Or Metastatic Disease) A Phase II Study Completed NCT00055692 Phase 2
49 A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) Completed NCT00881751 Phase 2 erlotinib hydrochloride;sorafenib tosylate
50 A Phase 2 Study of IMC-A12 (NSC742460) in Hepatocellular Carcinoma Completed NCT00639509 Phase 2

Search NIH Clinical Center for Adult Hepatocellular Carcinoma

Genetic Tests for Adult Hepatocellular Carcinoma

Anatomical Context for Adult Hepatocellular Carcinoma

MalaCards organs/tissues related to Adult Hepatocellular Carcinoma:

40
Liver, Testes, Endothelial, Colon, Breast

Publications for Adult Hepatocellular Carcinoma

Articles related to Adult Hepatocellular Carcinoma:

(show all 12)
# Title Authors PMID Year
1
Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer. 61
30288475 2018
2
Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. 61
29602016 2018
3
Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma. 61
26990031 2016
4
Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. 61
24002724 2014
5
FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo. 61
23544173 2013
6
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. 61
21922643 2012
7
Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors. 61
21788913 2012
8
Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. 61
21989430 2011
9
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. 61
19719772 2009
10
Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. 61
18525461 2008
11
Alpha(1)-antitrypsin deficiency, liver disease and emphysema. 61
12672469 2003
12
Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. 61
10847487 2000

Variations for Adult Hepatocellular Carcinoma

Cosmic variations for Adult Hepatocellular Carcinoma:

9 (show top 50) (show all 15388)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 3
2 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 3
3 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 3
4 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 3
5 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 3
6 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 3
7 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 3
8 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 3
9 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 3
10 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 3
11 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 3
12 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 3
13 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 3
14 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 3
15 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 3
16 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 3
17 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 3
18 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 3
19 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 3
20 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 3
21 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 3
22 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 3
23 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 3
24 COSM92703312 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 3
25 COSM92032561 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221= 14:67807621-67807621 3
26 COSM84360265 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.1979+14C>A p.? 5:32395145-32395145 3
27 COSM84362097 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 3
28 COSM85178149 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 3
29 COSM87884183 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 3
30 COSM127392053 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 3
31 COSM149268658 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 3
32 COSM149328017 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 3
33 COSM149281099 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 3
34 COSM144309108 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 3
35 COSM87420403 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 3
36 COSM98996636 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 3
37 COSM92255466 ZC3H15 liver,NS,carcinoma,hepatocellular carcinoma c.*55T>G p.? 2:186508788-186508788 3
38 COSM85044193 ZC3H14 liver,NS,carcinoma,hepatocellular carcinoma c.*10873G>A p.? 14:88622624-88622624 3
39 COSM106743522 ZBTB7B liver,NS,carcinoma,hepatocellular carcinoma c.*635G>C p.? 1:155017320-155017320 3
40 COSM93795261 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 3
41 COSM103188148 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 3
42 COSM91488114 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 3
43 COSM95291738 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 3
44 COSM107993551 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2383A>G p.I795V 8:80519295-80519295 3
45 COSM107993152 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2208A>G p.T736= 8:80518852-80518852 3
46 COSM86073785 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 3
47 COSM142300159 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1580A>G p.N527S 8:63187582-63187582 3
48 COSM90849676 YOD1 liver,NS,carcinoma,hepatocellular carcinoma c.*157T>C p.? 1:207048863-207048863 3
49 COSM90620829 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 3
50 COSM86902201 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167= 3:183722100-183722100 3

Expression for Adult Hepatocellular Carcinoma

Search GEO for disease gene expression data for Adult Hepatocellular Carcinoma.

Pathways for Adult Hepatocellular Carcinoma

GO Terms for Adult Hepatocellular Carcinoma

Molecular functions related to Adult Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleic acid binding GO:0003676 8.92 ZNF99 ZNF606 SUGP2 LIN28B

Sources for Adult Hepatocellular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....